Evolution of Interferon-Based Therapy for Chronic Hepatitis C
Hepatitis Research and Treatment · 2010
DOI: 10.1155/2010/140953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von Chun-Hao Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Division, Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 804, Taiwan. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Since 1986, interferon-alfa (IFN-) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN- was a major breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and is about 65% in HCV-2 or -3 patients. After 2000, pegylated interferon (PegIFN) much improved the rates of SVR. Presently, PegIFN--ribavirin combination therapy has been current standard of care for patients infected with HCV. In patients with HCV-1, treatment for 48 weeks is optimal, but 24 weeks of treatment is sufficient in HCV-2 or -3 infected patients. Clinical factors have been identified as predictors for the efficacy of the IFN-based therapy. The baseline factor most strongly predictive of an SVR is the presence of HCV-2 or -3 infections. Rapid virological response (RVR) is the single best predictor of an SVR to PegIFN-ribavirin therapy. If patients can't achieve a RVR but achieve a complete early virological response (cEVR), treatment with current standard of care can provide more than 90% SVR rate. HCV-1 patients who do not achieve an EVR should discontinue the therapy. Recent advances of protease inhibitor may contribute the development of a novel triple combination therapy.
Autor:innen und Institutionen
- Digestive Division, Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 804, Taiwan.
Zitieren
APA
Chen, C. H., & Yu, M. L. (2010). Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/140953
Vancouver
Chen CH, Yu ML. Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/140953
BibTeX
@article{Chen2010,
author = {Chen, Chun-Hao and Yu, Ming-Lung},
title = {Evolution of Interferon-Based Therapy for Chronic Hepatitis C},
journal = {Hepatitis Research and Treatment},
year = {2010},
doi = {10.1155/2010/140953}
}
EUVIMED